newsfilter
← Latest News
GlobeNewswire·

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET

  • Bicara Therapeutics Inc. (NASDAQ: BCAX) will report third quarter 2026 financial results & business updates before the market opens on Monday, November 9, 2026.
  • The company will host a conference call at 8:30 a.m. ET on the same day for discussion, with registration & dial-in details available via the provided link.
  • A live webcast will be accessible through the "Events & Presentations" section on the Bicara Investors page, with a replay available for 30 days.
  • Bicara is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors using a platform that targets tumors & delivers modulating payloads.
  • The lead program, ficerafusp alfa (formerly BCA101), is a bifunctional EGFR-directed monoclonal antibody bound to a TGF-β ligand trap designed to block cancer cell survival & immunosuppressive signaling.
  • Ficerafusp alfa is being developed for head & neck squamous cell carcinoma & other solid tumor types to address significant unmet medical needs.
  • Investor contact is Rachel Frank (IR@bicara.com) & media contact is Tim Palmer (Tim.Palmer@bicara.com).